# Éva Compérat

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/eva-comperat/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,164 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 83 |
| i10-index | 316 |
| Last Known Institution | University of Vienna |
| OpenAlex ID | https://openalex.org/A5063195568 |
| ORCID iD | https://orcid.org/0000-0001-8488-543X |
| Works | 736 |

## Researcher papers

- [European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines](https://scholariq.org/papers/european-association-of-urology-guidelines-on-muscle-invasive-and-metastatic/)
- [Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer](https://scholariq.org/papers/updated-2016-eau-guidelines-on-muscle-invasive-and-metastatic-bladder-cancer/)
- [The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours](https://scholariq.org/papers/the-2022-world-health-organization-classification-of-tumours-of-the-urinary/)
- [The Lancet Commission on prostate cancer: planning for the surge in cases](https://scholariq.org/papers/the-lancet-commission-on-prostate-cancer-planning-for-the-surge-in-cases/)
- [European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines](https://scholariq.org/papers/european-association-of-urology-guidelines-on-muscle-invasive-and-metastatic-2/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma](https://scholariq.org/papers/the-2021-updated-european-association-of-urology-guidelines-on-metastatic/)
- [Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old](https://scholariq.org/papers/clinicopathological-characteristics-of-urothelial-bladder-cancer-in-patients/)
- [EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†](https://scholariq.org/papers/eau-esmo-consensus-statements-on-the-management-of-advanced-and-variant-bladder/)
- [Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types](https://scholariq.org/papers/analysis-of-heritability-and-shared-heritability-based-on-genome-wide/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Researcher university

- [University of Vienna](https://scholariq.org/institutions/university-of-vienna/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.